Robert Ramirez, DO
Medical Oncology · Nashville, TNNPI 1669665808
Payments from drug & device makers
Across 334 payments — averaging $6225.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- E.r. Squibb & Sons, L.L.C.$204K
- Ipsen Biopharmaceuticals, Inc$144K
- AstraZeneca$105K
- Novartis$43K
- Advanced Accelerator Applications$27K
- plus $95K from 21 others
Across 1 payment — averaging $5820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 28 | $1,460,956 |
| E.r. Squibb & Sons, L.L.C. | 4 | $204,337 |
| Ipsen Biopharmaceuticals, Inc | 90 | $143,741 |
| AstraZeneca | 76 | $104,971 |
| Novartis | 12 | $43,455 |
| Advanced Accelerator Applications | 20 | $26,712 |
| Exelixis Inc. | 21 | $15,159 |
| Bayer | 12 | $15,145 |
| Genentech USA, Inc. | 13 | $14,115 |
| Curium US LLC | 27 | $14,105 |
| AbbVie | 4 | $9,164 |
| Bristol Myers Squibb | 2 | $8,933 |
| Tersera Therapeutics LLC | 6 | $5,062 |
| Regeneron Healthcare Solutions, Inc. | 4 | $3,371 |
| Lantheus Medical Imaging, Inc. | 2 | $2,875 |
| EMD Serono, Inc. | 1 | $2,100 |
| Amgen | 1 | $1,947 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Sun Pharmaceutical Industries Inc. | 1 | $1,000 |
| Galderma Laboratories, L.p. | 1 | $196 |
| Eisai Inc. | 1 | $186 |
| Lexicon Pharmaceuticals, Inc. | 2 | $170 |
| Karyopharm Therapeutics Inc. | 1 | $69 |
| Novocure Inc. | 1 | $43 |
| Aptevo Therapeutics Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Covidien LP | 1 | $12 |
How this compares
$2,079,363 in reported general payments places this provider in the 85th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Jennifer ChoeNashville$4.1M
- Cathy EngNashville$3.8M
- Jordan BerlinNashville$3.7M
- Kristen CiomborNashville$3.2M
- Vandana AbramsonNashville$3M
- Leora HornNashville$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.